iGlarLixi versus premixed insulin initiation in adults with type 2 diabetes advancing from basal insulin therapy: The SoliComplex real‐world study
Authors' conclusion
In this observational study in people with T2D suboptimally controlled on basal insulin, once-daily iGlarLixi was an effective treatment alternative to premixed insulin with significantly higher treatment persistence, similar adherence and HbA1c reduction, and numerically lower hypoglycaemia events, HRU and costs, regardless of age or baseline HbA1c.
Study context
- Population
- Adults (≥18 years) with T2D suboptimally controlled with basal insulin, US Optum Clinformatics databasematched cohort
- Participants
- 834 vs 834
- Exposure
- iGlarLixi vs premixed insulin
- iGlarLixin = 834
- Premixed insulinn = 834reference
- Outcome
- Treatment persistence in the overall population
- Follow-up
- 12 months
Methodological detailsreal-world, propensity-score matched
- Real-world
- Propensity-score matched
Main finding
Treatment persistence
Hazard ratio
0.88
95% CI 0.778–0.998
P = 0.0465
By group
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
Adherence and HbA1c reduction · 12 months
- Adherence and HbA1c reduction were similar between groups
Healthcare resource utilization (HRU) and costs · 12 months
- HRU and costs numerically lower for iGlarLixi
Subgroups: age ≥65 years and baseline HbA1c ≥9% · 12 months
- Outcomes consistent with those for the overall population
Safety
Hypoglycaemia events · 12 months
- Hypoglycaemia events numerically lower for iGlarLixi
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →